C-terminal cross-linking telopeptide as a serologic marker for bisphosphonate-related osteonecrosis of the jaw: review of 2 cases.
With the increasing use of the bisphosphonate class of drugs, dental professionals are encountering more cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ). The C-terminal cross-linking telopeptide (CTX) assay is a serologic test to predict the risk of BRONJ. This paper examines the effectiveness of CTX as a biochemical marker for BRONJ and its utility to the dentist in establishing appropriate treatment plans for patients with a history of bisphosphonate use. Alternative means of assessing the risk of BRONJ are discussed, and 2 case vignettes are presented to demonstrate dental treatment planning for patients with a history of bisphosphonate use, in the context of specific CTX results.
Dr. Michael Pasoff, 4-1350 Greene Ave, Westmount, QC H3Z 2B1. michael.pasoff@mail.mcgill.ca
Michael
M
Pasoff
D000293:Adolescent; D000328:Adult; D000369:Aged, 80 and over; D015415:Biomarkers; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000097:blood* / Q000175:diagnosis*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D024042:Collagen Type I / Q000097:blood*; D000075202:Contraindications; D003758:Dental Implantation, Endosseous; D019094:Dental Prosthesis, Implant-Supported; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D010455:Peptides / Q000097:blood*; D011237:Predictive Value of Tests; D059039:Standard of Care; D014081:Tooth Extraction; D055815:Young Adult
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide